Understanding how changes in glucocorticoid receptors contribute to drug resistance in prostate cancer
Official title: Posttranslational modifications of glucocorticoid receptor associated with drug-resistance in prostate cancer
Funded at State University of New York at Buffalo · NIH-11072124 · Data updated 2026-11-12
This study is looking at how changes in certain receptors in prostate cancer cells might make them resistant to treatments, and it aims to find new ways to help patients get better results from their therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | April 9, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $588,399 |
| NIH project number | 5R01CA290402-02 |
| Project ID | NIH-11072124 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer who have developed resistance to standard androgen-targeted therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not undergone androgen deprivation therapy may not benefit from this research.
What this research studies
This research investigates how modifications to glucocorticoid receptors can lead to resistance against treatments for advanced prostate cancer. It focuses on the role of these receptors in evading androgen deprivation therapy and how they can activate alternative survival pathways in cancer cells. By examining the phosphorylation of these receptors and their interaction with the AKT1 protein, the study aims to identify potential therapeutic targets to overcome drug resistance. Patients may benefit from insights that could lead to more effective treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that effectively combat drug resistance in advanced prostate cancer.
How similar studies have gone: Previous studies have shown promising results in targeting glucocorticoid receptors and AKT pathways in cancer treatment, indicating that this approach may be effective.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Adelaiye-Ogala, Remi — State University of New York at Buffalo
- Study coordinator: Adelaiye-Ogala, Remi
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.